- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
- Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
- Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
- Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
- Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Avalo Completes Divestiture of AVTX-800 Series
More ▼
Key statistics
On Monday, Avalo Therapeutics Inc (AVTX:NAQ) closed at 13.15, 232.90% above the 52 week low of 3.95 set on Jan 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.75 |
---|---|
High | 13.23 |
Low | 12.58 |
Bid | 9.25 |
Offer | 13.96 |
Previous close | 12.59 |
Average volume | 10.51k |
---|---|
Shares outstanding | 1.03m |
Free float | 974.82k |
P/E (TTM) | -- |
Market cap | 13.02m USD |
EPS (TTM) | -318.69 USD |
Data delayed at least 15 minutes, as of Jul 08 2024 20:56 BST.
More ▼